Project Grant R01AI175536
Award Date 8/18/25
Completion Date 7/31/29
Dollars Obligated $2.9M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $162,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of North Carolina at Chapel Hill. The grant supports research to characterize the mechanisms and parameters controlling gene amplification leading to phenotypic heterogeneity in Enterobacter bacteria, which can contribute to antibiotic resistance. The experiments aim to understand how certain Enterobacter...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $4,874,388 Cooperative Agreement under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to Duke University. The award, effective June 13, 2025, supports the "Center for Multiscale Immune Systems Modeling" (the Center of Excellence) - a multi-disciplinary research initiative focused on developing innovative solutions for multi-scale modeling in infectious and immune-mediated...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $233,250 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of North Carolina at Chapel Hill (UNC-CH). The purpose of this 2-year grant, with a start date of May 13, 2025, is to develop a novel platform for delivering therapeutic genetic payloads to targeted bacterial species within complex human microbiomes. Specifically, the research aims to engineer...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $501,011.00 to the University of North Carolina at Chapel Hill to conduct research on biodegradable polymeric microparticles comprised of acetalated dextran and their ability to induce immune tolerance. The goal is to develop an antigen-specific tolerance therapy for autoimmune diseases, an alternative to general...
- The University of North Carolina at Chapel Hill received a $420,553 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to develop a single-cell technique that reports the translational rate and transcriptome of individual bacterial cells. The project aims to explore the translational and transcriptomic heterogeneity in Staphylococcus aureus cells during chronic infection and long-term antibiotic treatment,...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, is supporting the development of a unique vaccine to prevent future pandemics caused by emerging coronaviruses. The $755,225 award to Loyola University of Chicago aims to create a T cell-inducing mucosal vaccine targeting conserved coronavirus antigens, which could provide cross-protection against sarbecoviruses and...
- This $421,067 Project Grant was awarded on August 8, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research at the University of North Carolina at Chapel Hill to investigate how neutrophil activities contribute to antibiotic treatment failure, particularly for Staphylococcus aureus infections. The research aims to delineate the mechanisms by which neutrophils induce antibiotic...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $791,661 Project Grant to Duke University. This 5-year grant, effective August 1, 2025 through July 31, 2030, will support research to optimize a vaccine delivery platform and multi-antigen strategy to elicit durable neutralizing antibodies and T-cell responses against HIV-1 infection. The research will leverage integrase-defective...
- This $156,080 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855). The grant was awarded to the University of Arizona to conduct research to uncover the underlying biology behind broadly neutralizing antibodies, which have the potential to provide evolution-proof protection against pathogens. The research aims to determine whether the rarity of broadly neutralizing antibodies...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $33,116,067 Cooperative Agreement to the University of California, Irvine (UCI) for the "Allergy and Infectious Diseases Research" program (CFDA 93.855). The award, titled "The UCI Vaccines for Pandemic Preparedness Center (VPPC)", aims to conduct basic and translational research to develop prototype vaccines against emerging viruses. The project will characterize and compare two universal,...